- Home
- SMXT vs NRXP Comparison
SMXT vs NRXP Comparison
Compare SMXT & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMXT
- NRXP
- Stock Information
- Founded
- SMXT 2008
- NRXP 2015
- Country
- SMXT United States
- NRXP United States
- Employees
- SMXT N/A
- NRXP N/A
- Industry
- SMXT
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- SMXT
- NRXP Health Care
- Exchange
- SMXT NYSE
- NRXP Nasdaq
- Market Cap
- SMXT 50.5M
- NRXP 51.3M
- IPO Year
- SMXT 2024
- NRXP N/A
- Fundamental
- Price
- SMXT $1.26
- NRXP $2.28
- Analyst Decision
- SMXT
- NRXP Strong Buy
- Analyst Count
- SMXT 0
- NRXP 3
- Target Price
- SMXT N/A
- NRXP $31.67
- AVG Volume (30 Days)
- SMXT 210.7K
- NRXP 464.9K
- Earning Date
- SMXT 03-05-2025
- NRXP 03-27-2025
- Dividend Yield
- SMXT N/A
- NRXP N/A
- EPS Growth
- SMXT N/A
- NRXP N/A
- EPS
- SMXT N/A
- NRXP N/A
- Revenue
- SMXT $28,793,764.00
- NRXP N/A
- Revenue This Year
- SMXT N/A
- NRXP N/A
- Revenue Next Year
- SMXT N/A
- NRXP N/A
- P/E Ratio
- SMXT N/A
- NRXP N/A
- Revenue Growth
- SMXT N/A
- NRXP N/A
- 52 Week Low
- SMXT $0.60
- NRXP $1.10
- 52 Week High
- SMXT $15.88
- NRXP $7.33
- Technical
- Relative Strength Index (RSI)
- SMXT N/A
- NRXP 38.85
- Support Level
- SMXT N/A
- NRXP $2.80
- Resistance Level
- SMXT N/A
- NRXP $3.07
- Average True Range (ATR)
- SMXT 0.00
- NRXP 0.29
- MACD
- SMXT 0.00
- NRXP -0.10
- Stochastic Oscillator
- SMXT 0.00
- NRXP 2.52
About SMXT SOLARMAX TECHNOLOGY INC
SolarMax Technology Inc is an integrated solar and renewable energy company. It operates in two segments namely the United States and China. The United States business includes the sale and installation of photovoltaic and battery backup systems. China operations consist of operating and maintaining solar farm projects and identifying and procuring solar farm projects for resale to third parties. Some of its products are LG Solar Panels, QCELL Solar Panels, Panasonic Solar Panels, and others. The company generates a majority of its revenue from the Solar energy systems.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.